肝癌患者血液RASSF1A基因甲基化的检测及其临床意义  

Detection of RASSF1A promoter hypermethylation in plasma of patients with primary hepatocellular carcinoma and its clinical significance

作　　者：仇小强[1] 陈罡[2] 余红平[1] 胡浪[1] 

机构地区：[1]广西医科大学公共卫生学院流行病学教研室,广西壮族自治区南宁市530021 [2]广西医科大学基础医学院病理教研室第一附属医院病理科,广西壮族自治区南宁市530021

出　　处：《世界华人消化杂志》2009年第1期90-93,共4页World Chinese Journal of Digestology

基　　金：广西医疗卫生重点科研基金资助项目;No200513~~

摘　　要：目的:探讨原发性肝细胞癌(HCC)患者血清中RASSF1A甲基化状况及RASSF1A甲基化作为一种新的肿瘤分子标志物在HCC早期无创性诊断中的意义和价值.方法:应用甲基化特异性PCR(MSP)技术检测35例HCC患者血清和10例健康对照血清中RASSF1A启动子区甲基化状况.结果:35例HCC患者血清中RASSF1A启动子区甲基化阳性率为40%,10份健康对照血清中未出现RASSF1A基因甲基化.RASSF1A基因甲基化与HCC患者性别、伴肝硬化、乙肝表面抗原、甲胎蛋白、肿瘤大小、有无包膜、有无门静脉癌栓及病理分级等临床病理参数无关.结论:RASSF1A基因甲基化在HCC的发生中起重要作用,RASSF1A基因甲基化可能是HCC新的肿瘤分子标志物.AIM： To investigate the promoter methylafion of Ras association domain family 1A （RASSFIA） in the serum of HCC and to explore the significance and value of the promoter methylation of RASSFIA as a new tumor molecular marker in early stage noninvasive diagnosis of HCC. METHODS： Promoter methylation of RASSF1A status in the serum of HCC patients （n = 35） and normal controls （n = 10） were detected by meth-ylation-specific PCR （MSP） RESULTS： RASSFIA promoter methylation was detected in 14 cases （40%） in the serum from 35 HCC patients, while no RASSFIA methylation was detected in 10 normal controls. No association was found between serum RASSFIA methylation and the clinicopathological parameters, such as sex, para-cirrhosis, HBV, AFP, tumor size, tumor capsular, portal vein tumor embolus or pathological grade. CONCLUSION： The promoter methylation of RASSFIA may play an important role in tumor genesis of HCC and act as a new tumor molecular marker for HCC.

关 键 词：原发性肝细胞癌 RASSF1A 启动子区甲 基化 血清 

分 类 号：R735.7[医药卫生—肿瘤]